Growth-hormone-releasing fragment (GRF 1-27)

What this is

Growth hormone-releasing factor-27 peptide (GRF 1-27) is a 27-residue N-terminal fragment of human growth hormone-releasing hormone (GHRH), the hypothalamic peptide that drives the pulsatile release of growth hormone (GH) from the anterior pituitary. It corresponds to amino acids 1 through 27 of the full-length 44-residue human GHRH and carries intact the most biologically active and evolutionarily conserved portion of the parent hormone. GRF 1-27 is not itself an approved drug — it is a research tool used to probe receptor pharmacology and to compare the structural requirements for GH secretagogue activity with synthetic peptides such as ipamorelin, GHRP-2, GHRP-6, and hexarelin.

History

GHRH was first isolated in 1982 from a pancreatic tumor that had caused acromegaly by overproducing a GH-releasing factor; Guillemin and colleagues published the 44-residue sequence in Science (Guillemin et al., Science 1982). Shortly after, researchers demonstrated that the entire intrinsic biological activity of GHRH resided in its first 29 amino acids: GHRH(1-29)-NH₂, known today as sermorelin, proved equipotent to longer forms in stimulating pituitary GH secretion (Prakash and Goa, BioDrugs 1999). This finding spurred systematic structure-activity work on N-terminal fragments. Meanwhile, comparative vertebrate biology identified the first 27 residues of GHRH as the single most evolutionarily conserved segment: across fish, amphibians, and mammals, the 1-27 region shows the highest sequence identity with human GHRH, and isolated fish GHRH(1-27) fragments were shown to retain cAMP-stimulating activity at recombinant GHRH receptors (Lee and colleagues, PNAS 2007). The 27-residue fragment has since appeared routinely in anti-doping reference tables as a comparison standard alongside sermorelin, tesamorelin, and CJC-1295 (Knoop and colleagues, Analytical and Bioanalytical Chemistry 2016).

What it does

GRF 1-27 retains the N-terminal receptor-activating core of human GHRH. When it engages the GHRH receptor (GHRHR) on pituitary somatotroph cells, it triggers GH synthesis and secretion through the same cAMP-driven pathway used by the full-length hormone (Halmos and colleagues, Reviews in Endocrine and Metabolic Disorders 2025). As a two-residue-shorter version of the minimally active sermorelin scaffold, it is used experimentally to map exactly which C-terminal residues matter for potency, and to establish a reference baseline against which more heavily engineered analogs — and structurally distinct GHSR-targeting secretagogues like ipamorelin and GHRP-6 — can be compared. Because both the GHRHR pathway (which GRF 1-27 follows) and the ghrelin receptor (GHSR1a) pathway (which ipamorelin and the GHRPs follow) ultimately converge on pituitary GH release, the fragment bridges the two pharmacological families in experimental settings.

Mechanism

GRF 1-27 is a fragment agonist of the GHRH receptor, a class B G-protein-coupled receptor. Cryo-EM structural work on GHRH-bound GHRHR showed that the peptide adopts an α-helical conformation spanning the extracellular domain and the transmembrane bundle, with Tyr1 at the N-terminus inserting deeply into the transmembrane domain core and forming hydrogen bonds essential for receptor activation — removal of Tyr1 abolishes biological activity entirely (Zhou and colleagues, Nature Communications 2020). The C-terminal segment of the peptide (residues beyond ~20) contacts the extracellular domain of the receptor in a two-step binding model, providing affinity while the N-terminal portion drives signalling. Upon receptor activation, adenylate cyclase is stimulated, intracellular cAMP rises, protein kinase A is activated, and CREB is phosphorylated, resulting in increased GH gene transcription and pulsatile GH secretion (Halmos and colleagues, Reviews in Endocrine and Metabolic Disorders 2025). The sequence YADAIFTNSYRKVLGQLSARKLLQDIM stored on this card is the bare backbone; no fatty-acid conjugation, PEGylation, or C-terminal amide modification is present, consistent with use as a minimal reference fragment rather than a stabilised clinical compound.

Evidence

• Human: No clinical trials for GRF 1-27 as an isolated peptide. The clinically related fragment sermorelin — GHRH(1-29)-NH₂, which extends GRF 1-27 by two residues — was shown to stimulate GH secretion equivalently to GHRH(1-40) when given intravenously, and was used therapeutically in children with idiopathic growth hormone deficiency, increasing mean height velocity from 4.1 cm/yr at baseline to 8.0 cm/yr after 6 months of treatment (Prakash and Goa, BioDrugs 1999). GRF 1-27 itself has not been evaluated in registered trials. No registered trials on ClinicalTrials.gov for "GRF 1-27" or "GHRH 1-27."
• Animal: Non-mammalian GHRH 1-27 fragments stimulate cAMP accumulation above background in receptor-transfected cell lines, confirming retained agonist activity at the GHRHR despite the two-residue truncation compared with sermorelin (Lee and colleagues, PNAS 2007).
• In vitro: Structure-activity studies on hGHRH(1-29)-NH₂ show that positions 1, 3, 5, 6, 10, 11, 13, 14, and 23 are critical for activity — all of which fall within the 1-27 window; alanine substitutions at those positions produce nearly complete loss of potency, while substitutions at positions 16, 18, 24, 25, 26, and 29 yield equipotent analogues (Cervini and colleagues, Journal of Medicinal Chemistry 1998).

Known effects

• Pituitary GH secretion — Agonist activity at GHRHR retained in the 1-27 fragment; full biological potency established for GHRH(1-29); GRF 1-27 extrapolated by analogy from comparative biology data (Preclinical / mechanistic)
• cAMP accumulation in GHRHR-expressing cells — Demonstrated for vertebrate GHRH(1-27) fragments in transfected cell lines (Preclinical)
• Receptor pharmacology reference — Used as a structural baseline to distinguish GHRHR-mediated GH release from GHSR1a-mediated release by ipamorelin, GHRP-2, GHRP-6, and hexarelin (Mechanistic only)

Safety signals

No clinical safety data exist for GRF 1-27 as a standalone compound. Sermorelin (the two-residue longer analogue) produced transient facial flushing and injection-site pain as the most commonly reported adverse events in clinical studies (Prakash and Goa, BioDrugs 1999). Native GHRH in plasma is rapidly cleaved at the NH₂ terminus by dipeptidyl aminopeptidase, producing a biologically inactive GRH(3-44) fragment with a plasma half-life of approximately 7 minutes in vivo; the intact 44-residue peptide has a half-life of approximately 7 minutes by HPLC measurement (Frohman and colleagues, Journal of Clinical Investigation 1986). GRF 1-27 would be expected to share this short plasma half-life given the same susceptibility of the Tyr1-Ala2 dipeptide bond to cleavage.

Regulatory status

• US: Not an approved drug. Sermorelin (GHRH 1-29-NH₂) was previously FDA-approved under the trade name Geref Pediatric but was voluntarily withdrawn from the US market by the manufacturer in 2008. Tesamorelin (an N-terminally modified 44-residue GHRH analog) remains FDA-approved for HIV-associated lipodystrophy (Egrifta, approved 2010).
• WADA: GHRH and all its fragments and analogues, including GRF 1-27, are prohibited in-competition and out-of-competition under the Prohibited List (S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics).
• Research use: Commercially available as a reference standard for anti-doping detection method development (Knoop and colleagues, Analytical and Bioanalytical Chemistry 2016).

Related peptides

• Sermorelin (GHRH 1-29-NH₂) — the two-residue longer fragment and the shortest synthetic peptide established to have full GHRH biological activity; the clinical benchmark for GRF 1-27 activity comparisons.
• Tesamorelin — a 44-residue N-terminally modified GHRH analog, FDA-approved for HIV-associated lipodystrophy, representing the longer-form GHRHR-targeting clinical agent related to this fragment.
• Ipamorelin, GHRP-2, GHRP-6, hexarelin — GHSR1a (ghrelin receptor) agonists that also stimulate pituitary GH release but through a structurally and pharmacologically distinct receptor; compared experimentally with GHRHR-targeting fragments like GRF 1-27 to separate receptor-pathway contributions to GH secretion.